Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Active
75A50126R00001_RFP_NPIVS_27Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

BARDA is seeking contractors to support the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The selected providers will be responsible for furnishing all necessary personnel, materials, and facilities to produce vaccines, antigens, and adjuvants for pandemic preparedness and public health emergencies. This includes generating and submitting critical analytical, clinical, and manufacturing data to the FDA to ensure rapid regulatory decisions and manufacturing readiness. To be eligible for this award, offerors must have experience producing vaccines against influenza and strains with pandemic potential. Mandatory qualifications include either holding a U.S. influenza vaccine license or demonstrating the development of an influenza vaccine through the submission of a Biologics License Application for seasonal or pandemic vaccines. This solicitation is managed by the Department of Health and Human Services with a response deadline of October 30, 2026.

General Info

BARDA seeks experienced contractors to produce pandemic influenza vaccines, antigens, and adjuvants.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda DcmaView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Documents

(19)

09-75A50126R00001_RFP+Att+9+ACH+Vendor+Misc+Payment+Enrollment+Form.docx

DOCX

14-75A50126R00001_RFP+Att+14+Past+Perfomance+Questionnaire+Template.docx

DOCX

16-75A50126R00001_RFP+Att+16+Bill+of+Materials+%28BOM%29+Template.xlsx

XLSX

19_75A50126R0001_RFP+Att+19+Surge+Manufacturing+and+Supply+Chain+Readiness+Assessment.pdf

PDF

07-75A50126R00001_RFP+Att+7+Breakdown+of+Proposed+Costs.xlsx

XLSX

08-75A50126R00001_+RFP+Att+8+Summary+of+Related+Activities.docx

DOCX

18-75A50126R00001_RFP+Att+18+BCP+SCP+Continuity+Plans.pdf

PDF

05-75A50126R00001_RFP+Att+4+Agent+Request+Form.docx

DOCX

15-75A50126R00001_RFP+Att+15+Contractor+Questions.xlsx

XLSX

01-75A50126R00001_RFP_Final.pdf

PDF

12-75A50126R00001_RFP+Att+12+HHS+Subcontracting+Plan+Template.docx

DOCX

10-75A50126R00001_RFP+Att+10+SF+LLL+Disclosure+of+Lobbying+Activities+Form.pdf

PDF

04-75A50126R00001_RFP+Att+3+Vendor+Production+Facilities.xlsx

XLSX

06-75A50126R00001_RFP+Att+5+BARDA+Dose+Tracker+Template.xlsx

XLSX

03-75A0126R00001_RFP+Att+2+ASPR+Security+Requirements.pdf

PDF

11-75A50126R00001_RFP+Att+11+SF+LLL+Disclosure+of+Lobbying+Activities+Form+Instructions.pdf

PDF

13-75A50126R00001_RFP+Att+13+Risk+Mitigation+Plan+Matrix+Template.docx

DOCX

02-75A50126R00001_RFP+Att+1+Prod+Handling+Guidance+Don+Nat.pdf

PDF

17-75A50126R00001_RFP+Att+17+Manufacturing+Plan.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
Contacts1 person available
OfficeWASHINGTON, DC, 20515, USA
Organization / Agency
Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
View Agency Profile
Office AddressWASHINGTON, DC, 20515, USA
Contacts
Laura Saddison

Full Description

Show more

BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.


Mandatory Qualification Requirements:


To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by:


1. Holding a U.S. influenza vaccine license; or


2. Have developed an influenza vaccine as evidenced by:


                                 a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine


Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

about 13 hours ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts
Defense Health Agency

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem Cells
Solicitation # NIH-NOI-PCA-NIA-01590
The National Institute on Aging (NIA), under the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), has issued a Notice of Intent to Sole Source for the validation and optimization of ONE-STEP tagging in human induced pluripotent stem cells (iPSCs). This acquisition aims to support the iPSC Neurodegenerative Disease Initiative (iNDI) and the Center of Alzheimer’s Disease and Related Dementias (CARD) by generating functionally engineered iPSC lines for research into Alzheimer’s disease and related dementias. The project involves high-activity guide identification, Bxb1 mRNA and cargo plasmid delivery optimization, and the generation of ADRD variant, MAPT 4R, and wild-type process-control clones. All deliverables must be repository-ready, meeting strict quality control standards including long-read sequencing, karyotype analysis, and SNP arrays to ensure scientific continuity and data integrity. The government intends to award this contract to The Jackson Laboratory, citing them as the only responsible source capable of meeting the requirements under FAR 6.302-1 and FAR 13.501(a). This determination is based on the laboratory's unique continuity with the existing iNDI program, established workflows for specific background lines, and proven success in large-scale CRISPR/Cas9 engineering. The total estimated contract value is 3,353,115.00 dollars, covering a base year from September 1, 2026, to August 31, 2027, and an option year extending to August 31, 2028. While this is a sole-source intent, the government will consider capability statements from other sources submitted by August 21, 2026, to determine if adequate competition exists.
National Institutes Of Health Olao

POSTED

3 days ago

DEADLINE

in 1 day
View Details

More opportunities from Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Same awarding agency